Document Detail


Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas.
MedLine Citation:
PMID:  20479645     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
In this study we examine the use of the concentration of thymidine kinase 1 in serum (STK1) as a prognostic factor in routine clinical settings. For this purpose we used sera from patients with oesophageal (n=101) and cardial (n=39) carcinomas and nonsmall-cell lung carcinoma (NSCLC) (n=157). Sera from healthy individuals (n=95) were used as controls. STK1 was analysed by a chemiluminiscence dot blot assay. The mean STK1 concentrations and the STK1 positive rates of the patients with oesophageal and cardial carcinomas and with NSCLC were significantly higher as compared with healthy controls (P=0.01). The mean STK1 value of oesophageal carcinoma patients correlated with T-values (P=0.021) and with stage (P<0.005), but not with grade. The mean STK1 value of cardial carcinoma patients did not correlate with grade. No data on stage and T-values were available for these patients, due to advanced disease. The mean STK1 value of NSCLC patients with squamous cell carcinoma was significantly higher as compared with adenocarcinoma type (P=0.024). The mean STK1 value of the NSCLC patients correlated with clinical grade (P=0.006), T-values (P=0.001), stage (P=0.035) and to size of the tumour (P=0.030). The mean STK1 value and the number of STK1 positive patients were also higher in recurrent NSCLC patients. There was a tendency that stage I-II NSCLC patients with an STK1 level above 2 pmol/l showed a higher frequency of recurrence/death than patients below 1 pmol/l. Our results show that STK1 is a useful marker for prognosis in patients with oesophageal, cardial and lung carcinomas.
Authors:
Zhishan Li; Yinghong Wang; Jie He; Jie Ma; Liang Zhao; Hengqi Chen; Ning Li; Ji Zhou; Ellen He; Sven Skog
Related Documents :
16029805 - An association between preoperative anemia and decreased survival in early-stage non-sm...
20523085 - Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking ...
10442375 - Adjuvant treatment of early stage non-small-cell lung cancer.
20035185 - A novel histopathological evaluation method predicting the outcome of non-small cell lu...
19075265 - Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsen...
22802745 - Personalized combined modality therapy for locally advanced non-small cell lung cancer.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)     Volume:  19     ISSN:  1473-5709     ISO Abbreviation:  Eur. J. Cancer Prev.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-06-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9300837     Medline TA:  Eur J Cancer Prev     Country:  England    
Other Details:
Languages:  eng     Pagination:  313-8     Citation Subset:  IM    
Affiliation:
Department of Thoracic Surgery Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Science, Beijing, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I...
Next Document:  Validation of My Family Health Portrait for six common heritable conditions.